Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30666086 | 0.77 | CYP11B2 (0.41) | CYP11B2CYP11B1TDP1L3MBTL1TRPV4 | |
| SCHEMBL5212018 | 0.77 | CYP11B2 (0.41) | CYP11B2CYP11B1TDP1L3MBTL1TRPV4 | |
| SCHEMBL30666087 | 0.77 | CYP11B2 (0.41) | CYP11B2CYP11B1TDP1L3MBTL1TRPV4 | |
| SCHEMBL1641172 | 0.77 | HRH4 (0.45) | CYP11B2CYP11B1TDP1L3MBTL1TSHR | |
| SCHEMBL31253097 | 0.77 | HRH4 (0.45) | CYP11B2CYP11B1TDP1L3MBTL1TSHR | |
| SCHEMBL21928096 | 0.76 | EGLN2 (0.40) | CYP11B2CYP11B1TDP1L3MBTL1TSHR | |
| SCHEMBL24417209 | 0.74 | USP8 (0.36) | TSHRCYP1A2CYP2C19KDM4EMEN1 | |
| SCHEMBL18121299 | 0.74 | KHK (0.48) | CYP11B2CYP11B1TDP1TRPV4CYP1A2 | |
| SCHEMBL21657144 | 0.74 | TSHR (0.37) | CYP11B2CYP11B1TDP1L3MBTL1TSHR | |
| SCHEMBL559359 | 0.74 | NOS3 (0.52) | TSHRARCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114361590-B | Electrolyte additive for lithium ion battery, electrolyte and lithium ion battery | 松山湖材料实验室 | 2023-07-25 | — | — | CN | claimed |
| CN-114361590-A | Lithium ion battery electrolyte additive, electrolyte and lithium ion battery | 松山湖材料实验室 | 2022-04-15 | — | — | CN | claimed |
| EP-3339287-B1 | NEW TYPE OF ANTIVIRAL COMPOUND | INST MED BIOTECHNOLOGY CAMS (CN) | 2020-07-01 | — | — | EP | claimed |
| US-10252987-B2 | Type of antiviral compound | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2019-04-09 | — | — | US | claimed |
| US-20180208549-A1 | NEW TYPE OF ANTIVIRAL COMPOUND | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2018-07-26 | — | — | US | claimed |
| EP-3339287-A1 | NEW TYPE OF ANTIVIRAL COMPOUND | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2018-06-27 | — | — | EP | claimed |
| CN-106467501-A | Novel antivirus compound | 中国医学科学院医药生物技术研究所 | 2017-03-01 | — | — | CN | claimed |
| CN-118574821-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
| CN-114361590-A | Lithium ion battery electrolyte additive, electrolyte and lithium ion battery | 松山湖材料实验室 | 2022-04-15 | — | — | CN | disclosed |
| EP-3339287-B1 | NEW TYPE OF ANTIVIRAL COMPOUND | INST MED BIOTECHNOLOGY CAMS (CN) | 2020-07-01 | — | — | EP | disclosed |
| US-20200181077-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2020-06-11 | — | — | US | disclosed |
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-17 | — | — | US | disclosed |
| EP-1934206-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039172-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1747206-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
| WO-2005111003-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | CYP11B2 1266/4885CYP11B1 1769/4885TDP1 1068/4885 |
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | P2RX7, P2RX2, P2RX5 | CYP11B2 678/4885CYP11B1 729/4885TDP1 1863/4885 |
| US-20200181077-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | CYP11B2 1324/4885CYP11B1 1133/4885TDP1 756/4885 |
| US-10252987-B2 | Type of antiviral compound | ZC3HAV1, ZC3HAV1L, EIF2AK2 | CYP11B2 2226/4885CYP11B1 2497/4885TDP1 2706/4885 |
| US-20180208549-A1 | NEW TYPE OF ANTIVIRAL COMPOUND | ZC3HAV1, ZC3HAV1L, EIF2AK2 | CYP11B2 2257/4885CYP11B1 2486/4885TDP1 2698/4885 |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | P2RX7, P2RX2, P2RX5 | CYP11B2 678/4885CYP11B1 729/4885TDP1 1863/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | CYP11B2 704/4885CYP11B1 736/4885TDP1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.